In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tularik Inc.

Division of Amgen Inc.

Latest From Tularik Inc.

NGM Aims For Three Drugs In Clinical Trials, Padded By Cash From Merck

Privately held NGM Biopharmaceuticals is investing in another dozen preclinical compounds, fueled in part by a rich deal with Merck & Co. that also enables employee expansion, Jeff Jonker explains in interview.

BioPharmaceutical Business Strategies

Deals Of The Week Wonders: Who Will Buy Onyx?

Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.

BioPharmaceutical Deals

Financings Of The Fortnight: Third Rock Bets Big on Global Blood Therapeutics’ Allosteric Modulators

Plus news on recent financial activity by Igenica, PhaseBio Pharmaceuticals, Seldar Pharmaceuticals and BioMarin Pharmaceutical.

Business Strategies

ATV Moves West Where the Devices Are

Advanced Technology Ventures, is an example of a venture firm that got into health care investing by initially focusing on medical devices in 1986. In order to remain closely involved with device start-ups, ATV has beefed up its presence in the hub of device innovation, the San Francisco area.
BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Amgen Inc.
  • Senior Management
  • David V Goeddel, PhD, CEO
    Jack Anthony, SVP, Bus. & Comm. Dev.
    Mary Jean Stempien, MD, VP, Clinical Dev.
  • Contact Info
  • Tularik Inc.
    Phone: (650) 825-7000
    2 Corporate Dr.
    S. San Francisco, CA 94080